Efficacy and safety of a combination of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis-Reference-Cited by-同舟云学术

Efficacy and safety of a combination of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis

Published:2017-11-06 Issue:1 Volume:17 Page:1-7
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Leung Henry W. C.¹,Leung John-Hang²,Chan Agnes L. F.²

Affiliation:

1. Department of Radiation Oncology, An Nan Hospital, China medical University, Tainan, Taiwan

2. Department of Pharmacy, An-Nan Hospital, China Medical University, Tainan, Taiwan

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2018.1394454

Reference43 articles.

1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

2. Breast cancer research in Asia: Adopt or adapt Western knowledge?

3. Global Status of Advanced/Metastatic Breast Cancer 2005–2015 Decade Report. (cited 27 March 2017).ww.breastcancervision.com and www.abc-lisbon.org

4. Howlader N, Noone AM, Krapcho M, et al. eds. SEER Cancer Statistics Review. 1975–2013, Bethesda, MD: National Cancer Institute. based on November 2015 SEER data submission, posted to the SEER web site April 2016 (updated September 12 2016, 27 October 2016, date last accessed). http:// seer.cancer.gov/csr/1975_2013/

5. 453 Trends in survival in metastatic breast cancer

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of first‐line regimens for advanced HER2‐positive breast cancer: A Bayesian network meta‐analysis;Cancer Innovation;2024-05-22

2. Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups;Frontiers in Oncology;2022-08-18

3. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis;Future Oncology;2021-11

4. Cone-beam breast CT features associated with HER2/neu overexpression in patients with primary breast cancer;European Radiology;2020-01-03

5. The role of radiation therapy and systemic therapies in elderly with breast cancer;Translational Cancer Research;2020-01